Healthcare - Biotechnology - NASDAQ - US
$ 44.83
-3.9 %
$ 1.71 B
Market Cap
-10.05
P/E
CASH FLOW STATEMENT
-117 M
OPERATING CASH FLOW
141 M
INVESTING CASH FLOW
130 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Tarsus Pharmaceuticals, Inc.
| Net Income | -136 M |
| Depreciation & Amortization | 877 K |
| Capital Expenditures | -1.5 M |
| Stock-Based Compensation | 19.8 M |
| Change in Working Capital | 306 K |
| Others | 1.69 M |
| Free Cash Flow | -123 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (135.9) | (62.1) | (13.8) | (26.8) | (4.7) | (1.3) |
| Depreciation & Amortization | 0.9 | 0.3 | 0.3 | 96 K | 37 K | 1 K |
| Deferred Income Tax | 0 | 0 | 1.6 | 15 K | 0.3 | 0 |
| Stock Based Compensation | 19.8 | 13.5 | 8.5 | 0.8 | 18 K | 9 K |
| Other Operating Activities | (2.6) | 0.2 | 5.8 | 3.3 | 0.1 | (0.1) |
| Change in Working Capital | 0.3 | (1.0) | 1.4 | 1.5 | 0.5 | 0.1 |
| Cash From Operations | (117.5) | (49.0) | 3.7 | (21.1) | (3.7) | (1.2) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (1.5) | (0.5) | (0.6) | (0.5) | (0.2) | 7 K |
| Other Items | 142.1 | (144.1) | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | 140.6 | (144.6) | (0.6) | (0.5) | (0.2) | 7 K |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 0 | 28 K | 0 | 0 |
| Total Debt Repaid | 10.0 | 20.0 | 0 | 0 | 2.0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.6 | (0.4) | 21 K | 40.1 | 57.5 | 3.6 |
| Cash From Financing Activities | 130.2 | 94.0 | 21 K | 131.8 | 59.4 | 3.6 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | 153.3 | (99.7) | 3.2 | 110.2 | 55.6 | 2.4 |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (123.0) | (49.5) | 3.2 | (21.6) | (3.8) | (1.2) |